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Summary
Reperfusion injury remains one of the major problems in transplantation.
Repair from ischaemic acute renal failure (ARF) involves stimulation of
tubular epithelial cell proliferation. The aim of this exploratory study was to
evaluate the effects of preconditioning donor animals with rapamycin and
tacrolimus to prevent ischaemia–reperfusion (I/R) injury. Twelve hours
before nephrectomy, the donor animals received immunosuppressive drugs.
The animals were divided into four groups, as follows: group 1 control: no
treatment; group 2: rapamycin (2 mg/kg); group 3 FK506 (0, 3 mg/kg); and
group 4: FK506 (0, 3 mg/kg) plus rapamycin (2 mg/kg). The left kidney was
removed and after 3 h of cold ischaemia, the graft was transplanted. Twenty-
four hours after transplant, the kidney was recovered for histological analysis
and cytokine expression. Preconditioning treatment with rapamycin or tac-
rolimus significantly reduced blood urea nitrogen and creatinine compared
with control [blood urea nitrogen (BUN): P < 0·001 versus control and crea-
tinine: P < 0·001 versus control]. A further decrease was observed when rapa-
mycin was combined with tacrolimus. Acute tubular necrosis was decreased
significantly in donors treated with immunosuppressants compared with the
control group (P < 0·001 versus control). Moreover, the number of apoptotic
nuclei in the control group was higher compared with the treated groups
(P < 0·001 versus control). Surprisingly, only rapamycin preconditioning
treatment increased anti-apoptotic Bcl2 levels (P < 0·001). Finally, inflamma-
tory cytokines, such as tumour necrosis factor (TNF)-a and interleukin
(IL)-6, showed lower levels in the graft of those animals that had been pre-
treated with rapamycin or tacrolimus. This exploratory study demonstrates
that preconditioning donor animals with rapamycin or tacrolimus improves
clinical outcomes and reduce necrosis and apoptosis in kidney I/R injury.
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Ischaemia–reperfusion injury (I/R injury), the most impor-
tant non-immunological determinant of kidney injury, is
still one of the major problems in kidney transplantation. I/R
injury can increase acute rejection rate and decrease long-
term allograft survival. I/R injury in the kidney is expressed
as acute renal dysfunction, evidenced by acute tubular necro-
sis and apoptosis [1,2]. The deleterious effects of I/R injury
are triggered by a complex response involving damage-
associated molecular pattern molecules (DAMPs), oxygen
radical species, cytokines, chemokines and complement
[3,4]. These inflammatory events induce apoptosis and
necrosis in renal cells, initiated through either the mitochon-
drial pathway or the receptor-mediated pathway, such as
binding of tumour necrosis factor (TNF-a) to their corre-
sponding receptors [5]. During the past few years, it has been
documented that cell apoptosis in I/R injury is also associ-
ated with complement activation [6,7]. Both anaphylotoxin
(C3a, C5a) and I/R injury membrane attack complex mecha-
nisms have been proposed as means by which the comple-
ment cascade induces tissue injury in an animal model of
renal I/R injury [8,9]. Furthermore, the use of an anti-C5
antibody has been shown to prevent the development of
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apoptosis after renal and cardiac I/R injury [10]. I/R injury is
an antigen-independent inflammatory process that produces
tissue damage [11].
There are different strategies to choose from and different
potential intervention aspects of the natural development of
the disease. We could potentially modify factors related to
donors, preservation solutions and recipients. Treating the
donor with different drugs is among the new strategies to
improve the quality of procured organs in renal transplant;
for example, steroids and statins [12–14].
Rapamycin, an antibiotic that inhibits protein synthesis
through mammalian target of rapamycin (mTOR) signal-
ling, has been used to attenuate I/R injury immediately post-
transplant without promising results [15]. Tacrolimus, an
antibiotic that inhibits calcineurin, administered to donors
has been reported to attenuate I/R injury [16]. Following our
previous studies [17], in which a kidney autotransplant
model was used, we observed that rapamycin treatment was
more effective in the prevention of apoptosis, whereas treat-
ment with tacrolimus presented the lowest levels of acute
tubular necrosis (ATN), so we explored the synergic effects of
both drugs, rapamycin and tacrolimus, when they were
administered to the donor.
Although the effects of rapamycin on lymphocytes have
been investigated thoroughly, it is known that this drug also
has a direct effect on renal proximal tubular cell function
[18]. Repair from ischaemic acute renal failure involves
stimulation of tubular epithelial cell proliferation. Agents
impairing the ability of renal epithelium to proliferate, espe-
cially in the face of ongoing injury, may result in prolonged
periods of acute renal failure (ARF) or failure in recovery.
Several studies of ARF have shown augmented injury and
delay repair when rapamycin is given near the time of injury
[19,20]. The mechanism appears to involve a combination of
enhanced necrosis, increased apoptosis and decreased pro-
liferation of renal tubular epithelial cells. In contrast, it has
been demonstrated that treatment with rapamycin in the
recipient animals attenuated I/R injury in small bowel [21]
and kidney I/R injury [22,23]. Also it has been reported that
rapamycin has a potent preconditioning effect in an animal
model of heart I/R injury [24]. However, it is well known that
rapamycin could aggravate ischaemically injured organs,
increasing cell apoptosis and negatively affecting post-
transplantation recovery [15,20]. Conversely, tacrolimus is a
calcineurin inhibitor normally administered to receptors of
renal transplant to block the activation of nuclear factor of
activated T cells (NF-AT) [25]. Tacrolimus produces multi-
faceted attenuating actions on inflammatory damage occur-
ring after reperfusion. Lastly, pretreatment with tacrolimus
has been shown to provide liver and renal protection against
I/R injury in rats [26,27].
Although intervention in the preservation solution and
the receptor has always been the first choice, because of
insufficient evidence supporting a successful intervention in
the donor there has always been research into the adminis-
tration of immunosuppressive drugs to the donor. Before
transplantation, the kidney already contains several infil-
trated macrophages and T lymphocytes [28]. This inflam-
matory process, activated by cold ischaemia as well as brain
death, may be explained by changes in the kidney tissue itself
[29]. Another potential reason is that these inflammatory
mediators could be released from T lymphocytes and mac-
rophages infiltrated in the kidney. Therefore, the administra-
tion of rapamycin and tacrolimus to the donor could be
useful to inhibit the release of mediators from the graft [30].
Anticipating the inflammatory process through the admin-
istration of immunosuppressive drugs to the donor could be
one of the scenarios to reduce the graft immunogenicity.
In previous studies, we have used tacrolimus and rapa-
mycin separately, and we observed a reduction in the
in-situ generation of proinflammatory mediators and an
up-regulation of cytoprotective genes [17]. We hypothesized
that the combined use of rapamycin and tacrolimus treat-
ment in donor animals would be associated with the attenu-
ation of I/R injury. In addition, it has been observed that
rapamycin had a tendency to decrease apoptosis and that
tacrolimus had a tendency to decrease ATN. Therefore, we
have hypothesized that the combination of these two drugs




Male Wistar rats weighing 280–350 g were used for both
organ donors and recipients of the kidney graft. Animals
were submitted to a 12-h day/night cycle with access to water
and standard laboratory chow ad libitum. All animal experi-
ments were performed according to guidelines set by the US
National Institutes of Health (NIH publication no. 28,
revised 1996).
Immunosuppressive drugs
We used tacrolimus (Prograf, Gador, Bs As, Argentina),
medical grade, donated by Gador Argentina, and rapamycin
(Sirolimus, Wyeth, Bs As, Argentina), medical grade, donated
by Wyeth Argentina.
Operation procedure
Donor rats were anaesthetized with intraperitoneal (i.p.)
atropine 0·01 mg/kg, buprenorphine 0·04 mg/kg, diazepam
10 mg/kg and, 10 min later, with ketamine 100 mg/kg body
weight. The donors’ blood vessels and ureter were fully
separated. Subsequently, the kidney was flushed via the aorta
with 3 ml of 4°C cold Ringer lactate solution until it turned
homogeneously pale. The left kidney was then removed with
its vascular and ureteral pedicle and stored for 180 6 15 min
in cold Ringer lactate solution at 4°C.
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Recipients animals were nephrectomized bilaterally and
underwent transplantation as described elsewhere [31,32].
Briefly, after flushing grafts with 5 ml normal Ringer’s solu-
tion, arterial and venous anastomoses were performed as
end-to-side anastomoses to the aorta and inferior vena cava,
respectively. Finally, the anastomosis of the ureter with the
urinary bladder was constructed. The rat’s body temperature
was monitored and kept constant between 35 and 37°C in all
cases. Rats were allowed to recover on a warm blanket with
free access to water and standard laboratory chow ad libitum.
Twenty-four hours after the transplant procedure, blood
samples were obtained for analysis, then animals were sacri-
fied and kidneys were removed for histological evaluation.
Experimental design
One dose of immunosuppressive drugs was administered to
donor animals 12 h before nephrectomy. Doses and admin-
istration route were chosen according to previous reports
[17]. Donor rats were divided randomly into four groups:
Group 1 (control, n = 6): no immunosuppression was
administered.
Group 2 (rapa, n = 6): rapamycin (2 mg/kg, Sirolimus,
Wyeth, Argentina) by gavage.
Group 3 (FK506, n = 6): tacrolimus (0, 3 mg/kg, Prograf,
Gador, Argentina) by gavage.
Group 4 (rapa+ FK506, n = 6): tacrolimus (0, 3 mg/kg) +
rapamycin (2 mg/kg) by gavage.
None of the recipient animals received any immunosup-
pressive drug after transplantation. In addition, six rats
underwent a sham procedure.
Blood tests
Twenty-four hours before and after transplant the following
blood determinations were performed: blood urea nitrogen
(BUN), creatinine and C3 complement fraction (C3). C3 was
measured by radial immunodiffusion and BUN and creati-
nine by ultraviolet kinetic and colorimetric-kinetic, respec-
tively (Mindray 300). Values are expressed in figures as the
difference between post-transplant and pretransplant were
defined for each group.
Renal histopathology
The anatomopathological samples were analysed by a
pathologist blind to group assignments. The kidneys were
fixed in a 10% neutral buffered formalin solution, embedded
in paraffin and used for histopathological examination.
Four micrometres-thick sections were cut, deparaffinized,
hydrated and stained with haematoxylin and eosin (H&E).
The renal sections were examined in a blinded fashion for
grade of cortical tubular epithelial necrosis. Counts were
performed in at least 10 different fields of square microme-
tres and assigned for severity of necrosis, using scores on
a scale of 1 (<5%), 2 (5–25%), 3 (25–50%), 4 (50–75%) and
5 (>75%) [23].
Terminal transferase deoxuridine triphosphate (dUTP)
nick end labelling (TUNEL) assay
TUNEL assay was performed according to the manufactur-
er’s instructions (Apoptag; Oncor, Gaithersburg, MD, USA).
Briefly, deparaffinized 4 mm-thick sections of paraffin-
embedded tissues were pretreated with 20 ml/ml Proteinase
K (Dako, Glostrup, Denmark) for 30 min at 37°C. After
washing, sections were incubated with digoxygenin-labelled
dUTP in the presence of terminal deoxynucleotidyl trans-
ferase. After the enzymatic reaction was blocked, sections
were incubated with a specific peroxidase-labelled anti-
digoxin antibody. Peroxidase was then reduced by 0·05
diaminobenzidine (Sigma, St Louis, MO, USA) in 0·1 ml/l
phosphate-buffered saline (PBS), pH 7·6 containing 1%
H2O2. After washing, the sections were lightly stained with
haematoxylin. Negative control reactions were performed
for each reaction step. They were obtained by omission of
terminal deoxynucleotidyl transferase, anti-digoxin anti-
body and peroxidase substrate. Positive controls included
sections of paraffin-embedded lymphoma of human origin.
The external medullar region was examined and the total
number of labelled nuclei was counted. Ten fields of 1 mm2
were examined by means of a reticulated lens.
Immunohistochemistry
Sections 4 mm thick were applied to poly-2-lysine coated
slides. Sections were dewaxed in xylene, dehydrated through
graded alcohols and water and then immersed in 0·3% vol/vol
H2O2 in methanol for 30 min to block endogenous peroxi-
dase. Antigens were reduced by microwaving at 750 W for
15 min in 0·01 mol/l trisodium citrate buffer, pH 6·0, then
rinsed well in standard PBS and non-specific binding was
blocked with 10% equine serum in PBS. Sections were incu-
bated with primary antibodies of monoclonal origin against
C3 (clone B-9) or with polyclonal from goat against TNF-a,
interleukin (IL)-6 and Bcl2 (Santa Cruz Biotechnology, Santa
Cruz, CA, USA). After being rinsed with PBS, sections were
incubated with biotinylated secondary antibodies. After-
wards, sections were rinsed with PBS and incubated with
avidin–biotin horseradish peroxidase complex according to
the manufacturer’s instructions (Vectastain Universal Quick
Kits; Vector Laboratories Ltd, Peterborough, UK). Peroxides
were visualized by incubating the sections in 3·3′ diami-
nobenzidine (Sigma Chemical Co., Poole, UK) and hydrogen
peroxide. Negative control experiments were performed
by omitting the incubation with the primary antibodies.
The presence of C3, TNF-a, IL-6 and Bcl2 was assessed in
10 consecutive cortex and medulla fields.
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Immunohistochemical area and optical
density determination
Images were captured from a microscope (Olympus BX50,
Tokyo, Japan) with a ¥4 objective through an attached digital
video camera (Olympus DP71, Tokyo, Japan) as TIF, RGB
images. The entire section was scanned with the help of a
motorized stage (Prior Scientific Inc., Rockland, MA, USA).
Stitched images were then analysed using image analysis
software (ImagePro Plus 6·3; Media Cybernetics Inc,
Bethesda, MD, USA). The entire section area of the slice was
calculated. To separate the positive immunostaining area
(brown stain) from the background, the colour segmenta-
tion function of the program was applied. A mask was then
applied to make the colour separation permanent. The
images were then transformed into 8-bit monochromatic.
After spatial and intensity of light calibration of the images,
the stained area and its optical density (OD), defined by the
antigen–antibody complex, were determined [33]. The
extension and the intensity of these markers was evaluated
and an immunohistochemical score (IS) was generated;
IS = (stained area/total area) ¥ intensity.
Statistical analysis
All values are expressed as mean 6 standard deviation of the
mean (s.d.). Analysis of variance (anova) was used to deter-
mine group differences. If the anova was significant, mul-
tiple comparisons were carried out using the Bonferroni
post-hoc test to locate the sources of differences. Non-
parametric variables were analysed with the Kruskal–Wallis
non-parametric anova. P < 0·05 was considered to indicate
a statistically significant difference.
Results
Plasma determination of BUN and creatinine
Plasma determinations were measured 24 h after transplant
procedure. Compared with the control group, BUN values
in the immunosuppressive treatment groups were signifi-
cantly reduced (BUN: control: 2·2 6 0·15 mg/dl; rapamycin
1·8 6 0·15 mg/dl; FK506 1·6 6 0·15 mg/dl; rapamycin +
FK506 1·3 6 0·1 mg/dl; P < 0·001 versus control) (Fig. 1a).
In the rapamycin + FK506 group, BUN values were signifi-
cantly lower than those in rapamycin or FK506 single treat-
ment (P < 0·001, P < 0·05, respectively). Among single
treatments, BUN level was lower in FK506 than with rapa-
mycin (P < 0·01). In the case of creatinine, compared with
control values, the immunosuppressive treatment groups
were reduced significantly (control: 4·7 6 1·34 mg/dl; rapa-
mycin 2·1 6 0·1 mg/dl; FK506 2 6 0·31 mg/dl; rapamycin +
FK506 1·1 6 0·13 mg/dl; P < 0·001 versus control) (Fig. 1b).
However, no variances were observed between the differ-
ent immunosuppressive treatments over creatinine levels
(P > 0·05). In the sham group, there were no differences in
urea and plasma creatinine between pre- and post-surgical
procedures (BUN pre-: 0·43 6 0·01 mg/dl and post-: 0·43 6
0·03 mg/dl P > 0·05; creatinine pre-: 0·88 6 0·06 mg/dl and
post-: 0·89 6 0·05 P > 0·05). These results in BUN and crea-
tinine suggest that immunosuppressive treatment applied
to the donor reduced post-transplant renal dysfunction
significantly.
Kidney damage
Necrosis and kidney damage were assessed with H&E-stained
kidney tissue 24 h after transplantation. Acute tubular necro-
sis score (ATN) was decreased significantly in the immuno-
suppressive treatment group compared with the control
group (4 6 0·63 in control; rapamycin 2·2 6 0·41; FK506
2 6 0·63; rapamycin + FK506 1·2 6 0·41; P < 0·001 versus
control; Fig. 2a). Figure 2b shows a representative image of
H&E stain for the evaluation of renal injury in each treatment
group. The use of rapamycin plus tacrolimus (group 4) was
associated with a lower level of acute tubular necrosis (ATN)
compared with rapamycin alone (P < 0·05), but no statistical
difference was observed in comparison with tacrolimus. Also,
the number of apoptotic nuclei in renal medulla was deter-
mined as evidence of kidney injury. In the control group,
the number of TUNEL-positive cells was higher compared
with the immunosuppressive treatment groups (control:
138·7 6 24·8; rapamycin: 22·3 6 4·5; FK506: 54·8 6 8·3 and
rapamycin + FK506: 17·5 6 5; P < 0·001 versus control,
Fig. 3a and b). As normal kidney control, the number of
positive apoptotic nuclei in sham animals was lower than
6/mm2 located only in deep medullary epithelial tubules (data
not shown). The use of rapamycin alone or rapamycin plus
tacrolimus showed a lower number of apoptotic nuclei cells
with respect to tacrolimus treatment (P < 0·05 and P < 0·01,
respectively). Finally, a statistically significant difference
in the expression of Bcl2 was detected in kidney tissue by








































Fig. 1. Plasma blood urea nitrogen (BUN) and creatinine after
transplantation. Twenty-four hours after transplantation blood
samples were obtained and serum parameters (a) BUN and (b)
creatinine were determined. Values are expressed as the difference
between post-transplantation minus pretransplantation for each
group. Values are mean 6 standard deviation (n = 6). *P < 0·05,
**P < 0·01 and ***P < 0·001 for comparison between groups.
No differences among sham animals were observed.
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immunohistochemistry. In accordance with our previous
results, Bcl2 levels in the control group were lower than in
the immunosuppressive treatment group (control: 1·8 6 0·5;
rapamycin: 16·01 6 4; FK506: 9 6 2·6 and rapamycin +
FK506: 6 6 1·25; P < 0·01 and P < 0·05 versus control, respec-
tively) (Fig. 3c). These results suggest that preconditioning
of the donor with rapamycin and tacrolimus or a combina-
tion of both is associated with lower kidney damage after
transplantation.
Complement C3 determination
In order to determine if the immunosuppressive treatment
affected the complement function, the C3 levels in recipient
animals were assessed. C3 plasma values in immunosup-
pressive treatment were significantly lower than control
group levels (control: 495 6 94 pg/ml; rapamycin: 166·7 6
57·1 pg/ml; FK506: 165 6 66·3 pg/ml and rapamycin +
FK506: 103·3 6 33·3.; P < 0·001 versus control, Fig. 4a). No
differences were found among the various immunosup-
pressive treatment groups (P > 0·05). In addition, the local
expression of C3 within the grafts was analysed. Immuno-
histochemical analysis of graft tissue 24 h after transplanta-
tion revealed that local expression of C3 was higher in the
control group compared with the immunosuppressive treat-
ment group (control: 53·98 6 4·5; rapamycin: 10·62 6 3·2;
FK506: 2·27 6 0·7 and rapamycin + FK506: 1·58 6 0·54.;
P < 0·001 versus control; Fig. 4b and c). There were no vari-
ances among the different drug treatments used (P > 0·05).
Cytokine expression
Finally, local expression of TNF-a and IL-6 was analy-
sed by immunohistochemistry in kidney tissue 24 h after
transplantation. Higher levels of TNF-a were observed
(control: 57·54 6 5·7; rapamycin: 2·7 6 0·99; FK506: 2·83 6
1·02 and rapamycin + FK506: 4·43 6 1·5; P < 0·001 versus
control) and IL-6 in the control group compared with
immunosuppressive treatment groups (control: 30·43 6 4·6;
rapamycin: 2·31 6 2·05; FK506: 3·73 6 3·6 and rapamycin +
FK506: 6·57 6 2·8; P < 0·001 versus control, Fig. 5). There
was no variance between the treatment groups (P > 0·05).
Discussion
This study suggests that a single dose of a combination of
rapamycin and tacrolimus given to donors could attenuate
the I/R injury caused by cold ischaemia. There appears to be
a clinical and histological improvement and reduction of
inflammatory mediators without administration of drugs in
the recipient after transplantation. To the best of our knowl-
edge, this is the first report to use an isogenic transplant
model to study the effects of combined preconditioning
treatment with rapamycin and tacrolimus in donors for
renal I/R injury.
Our findings are in line with previous studies demonstrat-
ing that preconditioning donors with calcineurin inhibitors
(CNI) can protect the kidney from I/R injury [16,34].
However, the basic mechanism behind CNI preconditioning
remains unknown. In our model, 24 h after the I/R injury
process, the presence of acute renal failure was expressed
clinically by plasmatic urea and creatinine increases and
expressed histopathologically by necrosis and apoptosis. Pre-
conditioning with immunosuppressive drugs applied to the
donor attenuated renal dysfunction, as BUN and plasma Cr
levels were reduced significantly with the immunosuppres-
sive treatment. The combined therapy with rapamycin and
tacrolimus generated lower levels of BUN and creatinine.
These results are in contrast with previous reports showing
that rapamycin alone or in combination with tacrolimus
delays recovery I/R injury in warm ischaemic models
[35,36]. We hypothesized that this dual effect of rapamycin,
depending on the time of administration, could be the
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Fig. 2. Kidney tubular damage after transplantation. (a) The acute
tubular necrosis score was graded in haematoxylin and eosin (H&E)
staining cortex according to particular histological findings from 1
to 5. Values are mean 6 standard deviation (n = 6). *P < 0·05 and
***P < 0·001 for comparison between groups. (b) Representative H&E
stain for the evaluation of renal injury after 24 h of
ischaemia–reperfusion.
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It should be noted that these studies were performed with
models of warm ischaemia and that immunosuppressants
were administered before and after the induction of I/R
injury. In our work, we used a model of cold ischaemia with
administration of immunosuppression to the donor only
before transplantation.
We cannot ignore that the effect of different immunosup-
pressants on I/R injury after renal transplantation is not
always clear. For example, cyclosporin has shown to impair
the recovery of renal allograft from delayed graft function
(DGF) [37]. In the case of rapamycin, Inman et al. have
demonstrated that rapamycin preserves function compared
with cyclosporin after I/R injury [22]. In contrast, several
authors have demonstrated that rapamycin treatment in I/R
injury was associated with elevated serum creatinine levels,
reduced proliferative response of renal tubular cells and
increased expression of transforming growth factor (TGF)-b
[38], leading to impaired renal recovery after I/R injury
[20,23]. In the immunostimulation setting after transplant,
rapamycin decreases lymphocyte proliferation and reduces
rejection [39]. Nevertheless, in the setting of renal injury,
where organ repair depends on tubular cell proliferation and
well-orchestrated apoptosis, rapamycin may be harmful. Lie-
berthal et al. [40] have demonstrated that rapamycin inhibits
proliferation and increases apoptosis of renal tubular epithe-
lial cells in vitro and in vivo. Furthermore, there is evidence of
pharmacokinetic interactions between rapamycin and CNI
that augment ischaemic injury and inhibit tissue repair when
used in combination [41]. Conversely, our results may dem-
onstrate that the combination of rapamycin and tacrolimus
administered to donors decreases apoptosis and necrosis in
the graft in a syngeneic rat model. The difference observed in
our experiments, compared to Lieberthal et al. [40], may
result from the administration setting. Once the injury
is caused, rapamycin delays ATN recovery but the early
administration of rapamycin, i.e. before the injury is caused,
may explain the different beneficial effects observed in
this exploratory study. Immunosuppressive treatment was
administered in a single dose only to donor animals, 12 h
before ablation. Several authors using the transplant model
with rapamycin exposure after I/R injury support the
hypothesis that rapamycin compromises renal function by
impairing recovery rather than increasing injury severity
[19,40]. In particular, Fuller et al. have demonstrated that
serum creatinine in rapamycin-treated groups takes longer
to recover [42]. These results show coherence regarding the
specific impact of rapamycin on injured kidney. The data
presented in our exploratory work could provide new evi-
dence for the use of rapamycin as a potent non-nephrotoxic
immunosuppressant for its use in donors in the DGF setting.
The exact mechanism underlying the effect described for
rapamycin or tacrolimus on renal I/R injury has not been
explained completely. The protection by donor precondition-
ing has been associated with a reduction in the inflammatory
response to reperfusion. Accordingly, the proinflammatory
cytokines TNF-a and IL-6 were reduced by donor precondi-
tioning with immunosuppressive treatment drugs. Other
studies have also described that rapamycin suppresses IL-6
production, and that this may be associated with regulatory T
cell (Treg) induction and with a decrease in the T helper 17
(Th1) population [43,44]. Regarding apoptosis, the improve-
ment observed in the rapamycin group could be explained by
Fig. 3. Apoptosis and Bcl2 expression.
(a) Apoptotic cells using the terminal
deoxynucleotidyl transferase deoxuridine
triphosphate (dUTP) nick end labelling
(TUNEL) method in outer and inner medulla.
The total number of labelled nuclei was
counted in 10 fields of 1 mm2. As normal
kidney control, the number of positive
apoptotic nuclei in sham animals was lower
than 6/mm2 located only in deep medullary
epithelial tubules. (b) Representative TUNEL
staining of kidney sample after 24 h of
reperfusion. Positive apoptotic cells appear with
brown stained nuclei in outer medulla and
cortex (A ¥ 100, scale bar = 100 m). (c)
Immunohistochemical score of Bcl2 in renal
tissue from transplanted rats. Quantitative
analysis of Bcl2 expression was assessed in 10
consecutive cortex and medulla fields. Values
are mean 6 standard deviation (n = 6).
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in-situ up-regulation of Bcl-2, a specifically anti-apoptotic
gene.Remarkably, the increased Bcl-2 expression could not be
observed in animals treated with tacrolimus, which also pre-
sented more TUNEL-positive cells than those animals treated
with rapamycin. However, preconditioning with tacrolimus
has a clear anti-apoptotic effect, as it has been shown that
tacrolimus diminishes the levels of Fas, Fas-ligand and
caspases 1 and 3, which occur with I/R injury [16]. The
decrease in apoptosis observed in immunosuppressive treat-
ment groups could be explained partially by the decreased
in-situ expression of TNF-a, a known inflammatory media-
tor related to extrinsic pathway of apoptosis inducing apop-
tosis in renal epithelial cells [45,46]. Similarly, the observed
decrease in C3 systemic and local levels could be another
reason to explain why preconditioning improves clinical out-
comes, as a relationship between apoptosis and complement
generation in I/R injury is well established [47,48]. In a warm
ischaemia model, Thurman et al. have shown even higher
systemic levels of C3 than in our results, although the mea-
surement was taken in a different time-frame (8 h post-I/R
injury) [49]. An up-regulated in-situ expression of C3 and
caspase 3 can be seen as soon as 2 h following I/R injury [50].
In our work, with a 3-h cold ischaemia model, the reduction
in plasmatic levels of C3 in immunosuppressive treatment
groups could be related to lower expression of C3 observed in
situ.Once again, the combined treatment with rapamycin and
tacrolimus presented the lowest levels of plasma C3 and local
C3 expression.
One of the most important approaches to administer
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Fig. 4. C3 determination after transplantation. (a) Plasma C3
complement fraction (C3) was measured by radial immunodiffusion.
Values are expressed as the difference between post-transplantation
minus pretransplantation for each group. (b) Presence of C3 was
assessed in 10 consecutive cortex and medulla fields. The extension
rather than intensity of these markers was evaluated using a
semiquantitative score. (c) Immunohistochemical demonstration of
C3 expression in kidney sections from transplanted animals without
treatment or treated with rapamycin, tacrolimus or the combination
of both (A ¥ 100). Values are mean 6 standard deviation (n = 6).


































Fig. 5. Score of tumour necrosis factor (TNF)-a and interleukin
(IL)-6 after transplantation. The score of TNF-a and IL-6 were
graded on a scale from 1 to 5 by using microscopic criteria as
described in Materials and methods. Values are mean 6 standard
deviation (n = 6). ***P < 0·001 for comparison to control group.
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study carried out by Farrar et al., showing that C3-deficient
kidneys are protected from ischaemic damage after post-
transplantation into syngeneic recipient mice with normal
serum complement activity; i.e. kidney-derived C3, not
serum C3, drives the expression of I/R injury [6]. C3 is
synthesized by tubular, mesangial and endothelial cells and
contributes to the inflammatory process in kidney trans-
plantation and is up-regulated rapidly after I/R [51].
Complement damaging effects depend mainly on the cleav-
age of C3, which is the central component on which all
activation pathways converge. This activation may occur via
the mannose-binding lectin pathway as well as through the
alternative pathway in kidney transplant [52]. C3 cleavage is
an essential part of the process ending in the membrane
attack complex synthesis which, in turn, could lead to TNF-a
and IL-6 production promoting injury [53]. The mechanism
by which both drugs attenuate local and systemic C3 expres-
sion is still unknown and needs to be explained.
In our exploratory study, the combination of a calcineurin
inhibitor and inhibitors of mTOR diminishes the in-situ
generation of proinflammatory mediators; in addition, this
combination up-regulates cytoprotective genes. As a result of
this process there is diminished necrosis and apoptosis of
tubular epithelial cells and, in turn, an improvement in renal
clinical function.
Several research groups are studying donor treatment
and it may be applied clinically in the near future.
However, our experimental model could not be transferred
directly to a cadaveric donor transplant model, because
brain death of the donor has not been considered. Brain
death is a strong proinflammatory event that results in the
activation of several pathways [54]. However, we believe
that the model could be clinically useful for those patients
with living donors who require prolonged bench surgery,
or for those patients included in donor pair program-
mes requiring a longer time of cold ischaemia. As there is
no evidence of immunosuppression to donors in living
donors, this issue should be debated within a bioethical
framework.
To our knowledge, this is one of the few studies showing
evidence of a lower I/R injury with combined immunosup-
pressive treatment of donors using a syngeneic rat model.
The use of immunosuppressive drugs administered to
donors has attenuated the I/R injury process and this was
demonstrated by a marked necrosis and apoptosis decrease
in renal tubular epithelial cells. Further studies based on
this exploratory study would describe the use of immuno-
suppressive treatment to the donor to improve the quality of
the organ to be transplanted.
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